2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.05 A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC

P4.11E.05 A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC

Back to course

Pdf Summary

This randomized phase II trial aimed to assess the myeloprotective effects of trilaciclib when used in combination with chemotherapy (carboplatin, paclitaxel) and the immune checkpoint inhibitor tislelizumab as a first-line treatment for advanced squamous non-small cell lung cancer (sqNSCLC). Conducted from August 2023 to August 2024, 32 patients were enrolled; 15 in the treatment group receiving trilaciclib, and 17 in the control group.<br /><br />The primary endpoint was the occurrence of grade 3 neutropenia during the induction period. The results showed that the treatment group had a lower incidence of grade 3/4 neutropenia (26.7%) compared to the control group (58.8%). Additionally, 33.3% of patients in the treatment group and 52.9% in the control group required granulocyte colony-stimulating factor (G-CSF) administration for neutropenia management. Fewer patients in the treatment group needed intravenous antibiotics (13.3%) compared to the control group (23.5%).<br /><br />Non-hematological adverse events were generally mild (grades 1-2), with serious adverse events (SAEs) occurring in 3 patients in each group. Grade 4 treatment-related adverse events (TRAEs) were reported in 41.2% of the control group but not in the treatment group.<br /><br />In terms of efficacy, the objective response rate (ORR) was slightly higher in the treatment group at 88.9% compared to 77.8% in the control group. The disease control rate (DCR) was 88.9% in the treatment group and 100% in the control group.<br /><br />The results suggest that trilaciclib may improve the tolerability of chemotherapy by reducing the incidence of severe neutropenia without compromising the antitumor efficacy in patients with advanced sqNSCLC. These findings indicate the potential benefits of trilaciclib in managing chemotherapy-induced myelosuppression while maintaining treatment effectiveness.

Asset Subtitle

Yongsheng Wang

Meta Tag

Speaker Yongsheng Wang

Topic Metastatic NSCLC – Immunotherapy

Keywords

trilaciclib

myeloprotective

chemotherapy

tislelizumab

sqNSCLC

neutropenia

granulocyte colony-stimulating factor

adverse events

objective response rate

disease control rate